Adjuvant Therapy in Muscle-Invasive Bladder Cancer and Upper Tract Urothelial Carcinoma

Affiliations

¹ Department of Medicine, Division of Hematology-Oncology, University of Pittsburgh Medical Center, 5150 Centre Avenue, Pittsburgh, PA 15232, USA.
² Department of Medicine, Division of Medical Oncology, University of Kansas Medical Center, 2330 Shawnee Mission Parkway, Suite 210, MS 5003, Westwood, KS 66205, USA. Electronic address: rparikh2@kumc.edu.

Review

Tala Achkar et al. Urol Clin North Am. 2018 May.

. 2018 May;45(2):257-266.

doi: 10.1016/j.ucl.2017.12.010. Epub 2018 Feb 21.

¹ Department of Medicine, Division of Hematology-Oncology, University of Pittsburgh Medical Center, 5150 Centre Avenue, Pittsburgh, PA 15232, USA.
² Department of Medicine, Division of Medical Oncology, University of Kansas Medical Center, 2330 Shawnee Mission Parkway, Suite 210, MS 5003, Westwood, KS 66205, USA. Electronic address: rparikh2@kumc.edu.

Abstract

This article summarizes the role of adjuvant chemotherapy in muscle-invasive and transitional cell carcinoma of the bladder and upper urinary tract.

Keywords: Adjuvant chemotherapy; Micrometastases; Muscle-invasive bladder cancer (MIBC); Neoadjuvant chemotherapy; Urothelial cancer.